Nectar Lifesciences Limited, a prominent player in the pharmaceutical industry, has announced a significant change in its senior management. Mr. Ashok Kumar, the company's Vice President of Exports, has tendered his resignation, effective November 9, 2025.

Resignation Details

According to the company's official communication to the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), Mr. Kumar cited personal reasons for his departure. In his resignation letter addressed to CEO Mr. Amit Chadah, Kumar requested immediate relief from his responsibilities.

Corporate Disclosure

In compliance with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations, Nectar Lifesciences promptly informed the stock exchanges about this senior management change. The company provided the following details as required by the LODR Regulations:

Additional Corporate Updates

In a separate announcement, Nectar Lifesciences also notified the stock exchanges about an upcoming board meeting. The meeting is scheduled for Friday, November 14, 2025, to consider and approve the Unaudited Financial Results for the quarter and half year ended on September 30, 2025, among other matters.

This management change and the upcoming financial review highlight the company's commitment to transparency and adherence to regulatory requirements. Investors and stakeholders will be keenly watching how these developments might impact Nectar Lifesciences' future strategies, particularly in its export operations.

In a significant corporate action, SBICAP Trustee Company Limited has released its pledge on a substantial portion of Nectar Lifesciences Limited's equity shares. This move has resulted in a notable change in the shareholding pattern of the pharmaceutical company.

Key Details of the Pledge Release

Impact on Shareholding

The release of pledge has led to a complete exit of SBICAP Trustee Company Limited from Nectar Lifesciences' shareholding structure. Prior to this action, SBICAP Trustee held a significant 44.35% stake in the company through pledged shares.

Company Share Capital

Nectar Lifesciences Limited's share capital structure remains unchanged:

Additional Information

It's important to note that SBICAP Trustee Company Limited does not belong to the promoter group of Nectar Lifesciences. This pledge release was executed in compliance with regulatory requirements, as evidenced by the disclosure made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The official communication regarding this transaction was sent to the BSE Limited on November 3, 2025, by SBICAP Trustee Company Limited, detailing the release of pledge and the subsequent change in shareholding.

This development may have implications for Nectar Lifesciences' ownership structure and could potentially impact the company's future strategic decisions. Investors and market watchers will likely keep a close eye on any further developments or changes in the company's shareholding pattern following this significant pledge release.